European Journal of Cancer
Volume 46, Issue 5 , Pages 901-911 , March 2010

Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours

  • Hester van Cruijsen

      Affiliations

    • Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    • ,
  • Emile E. Voest

      Affiliations

    • Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
    • ,
  • Cornelis J.A. Punt

      Affiliations

    • Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands
    • ,
  • Klaas Hoekman

      Affiliations

    • Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    • ,
  • Petronella O. Witteveen

      Affiliations

    • Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
    • ,
  • Martijn R. Meijerink

      Affiliations

    • Department of Radiology, VU University Medical Center, Amsterdam, The Netherlands
    • ,
  • Thomas A. Puchalski

      Affiliations

    • AstraZeneca, Wilmington, DE, USA
    • Present address: Centocor, Chesterbrook, PA, USA.
    • ,
  • Jane Robertson

      Affiliations

    • AstraZeneca, Alderley Park, Macclesfield, UK
    • ,
  • Owain Saunders

      Affiliations

    • AstraZeneca, Alderley Park, Macclesfield, UK
    • ,
  • Juliane M. Jürgensmeier

      Affiliations

    • AstraZeneca, Alderley Park, Macclesfield, UK
    • ,
  • Carla M.L. van Herpen

      Affiliations

    • Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands
    • ,
  • Giuseppe Giaccone

      Affiliations

    • Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    • Corresponding Author InformationCorresponding author: Address: Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Building 10, Room 12N226, 10 Center Drive, Bethesda, MD 20892-190, USA. Tel.: +1 301 496 4916; fax: +1 301 402 0172.

Received 23 September 2009 ,Revised 7 December 2009 ,Accepted 14 December 2009.

References 

  1. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25:581–611
  2. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995;19:183–232
  3. Brabender J, Danenberg KD, Metzger R, et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res. 2001;7:1850–1855
  4. van Cruijsen H, Giaccone G, Hoekman K. Epidermal growth factor receptor and angiogenesis: opportunities for combined anticancer strategies. Int J Cancer. 2005;117:883–888
  5. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70
  6. Jung YD, Mansfield PF, Akagi M, et al. Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. Eur J Cancer. 2002;38:1133–1140
  7. Shaheen RM, Ahmad SA, Liu W, et al. Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Brit J Cancer. 2001;85:584–589
  8. Herbst RS, O’Neill VJ, Fehrenbacher L, et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol. 2007;25:4743–4750
  9. Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 2005;65:4389–4400
  10. Drevs J, Siegert P, Medinger M, et al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2007;25:3045–3054
  11. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669–676
  12. Karkkainen MJ, Haiko P, Sainio K, et al. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol. 2004;5:74–80
  13. Tammela T, Zarkada G, Wallgard E, et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature. 2008;454:656–660
  14. Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol. 2001;19:843–850
  15. Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008;372:1809–1818
  16. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–216
  17. Voest EE, van Cruijsen H, van Herpen CML, et al. Evaluation of thyroid function in an open-label Phase I study of AZD2171 with gefitinib. Eur J Cancer 2007;5(Suppl) [abst 705].
  18. Baselga J, Rischin D, Ranson M, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol. 2002;20:4292–4302
  19. Ranson M, Hammond LA, Ferry D, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol. 2002;20:2240–2250
  20. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005;366:1527–1537
  21. Veronese ML, Mosenkis A, Flaherty KT, et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol. 2006;24:1363–1369
  22. Holden SN, Eckhardt SG, Basser R, et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol. 2005;16:1391–1397
  23. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. New Engl J Med. 2003;349:427–434
  24. Cobleigh MA, Langmuir VK, Sledge GW, et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol. 2003;30:117–124
  25. Perez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol. 2004;22:3238–3247
  26. Gelderblom H, Verweij J, Steeghs N, et al. Phase I, safety, pharmacokinetic and biomarker study of BAY 57-9352, an oral VEGFR-2 inhibitor, in a continuous schedule in patients with advanced solid tumors. J Clin Oncol 2006;24(S18) [abst 3040].
  27. Schoeffski P, Wolter P, Himpe U, et al. Sunitinib-related thyroid dysfunction: a single-center retrospective and prospective evaluation. J Clin Oncol 2006;24(18S) [abst 3092].
  28. Shaheen PE, Tamaskar IR, Salas RN, et al. Thyroid function tests (TFTs) abnormalities in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib. J Clin Oncol 2006;24(18S) [abst 4605].
  29. Desai J, Dileo P, Morgan JA, et al. Hypothyroidism may accompany SU11248 therapy in a subset of patients (pts) with metastatic (met) gastrointestinal stromal tumors (GIST) and is manageable with replacement therapy. J Clin Oncol 2005;23(16S) [abst 3040].
  30. Desai J, Yassa L, Marqusee E, et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med. 2006;145:660–664
  31. Adjei AA, Molina JR, Mandrekar SJ, et al. Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer. Clin Cancer Res. 2007;13:2684–2691
  32. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. New Engl J Med. 2007;356:125–134
  33. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New Engl J Med. 2007;356:115–124
  34. Motzer RJ, Amato R, Todd M, et al. Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs. 2003;21:99–101
  35. Dawson NA, Guo C, Zak R, et al. A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma. Clin Cancer Res. 2004;10:7812–7819
  36. Jermann M, Stahel RA, Salzberg M, et al. A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma. Cancer Chemother Pharmacol. 2006;57:533–539
  37. Sridhar SS, Mackenzie MJ, Hotte SJ, et al. Activity of cediranib (AZD2171) in patients (pts) with previously untreated metastatic renal cell cancer (RCC). A phase II trial of the PMH Consortium. J Clin Oncol 2008;26(15S) [abst 5047].
  38. Drevs J, Zirrgiebel U, Schmidt-Gersbach CI, et al. Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. Ann Oncol. 2005;16:558–565
  39. Ebos JM, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci USA. 2007;104:17069–17074
  40. Meijerink MR, van Cruijsen H, Hoekman K, et al. The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients. Eur Radiol. 2007;17:1700–1713
  41. Bukowski RM, Kabbinavar FF, Figlin RA, et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol. 2007;25:4536–4541
  42. Hainsworth J, Herbst RS. A phase III, multicenter, placebo-controlled, double-blind, randomized clinical trial to evaluate the efficacy of bevacizumab (Avastin) in combination with erlotinib (Tarceva) compared with erlotinib alone for treatment of advanced non-small-cell lung cancer after failure of standard first-line therapy (BETA). J Thorac Oncol. 2008;3:S302

PII: S0959-8049(09)00935-6

doi: 10.1016/j.ejca.2009.12.023

European Journal of Cancer
Volume 46, Issue 5 , Pages 901-911 , March 2010

Article Tools

* Image Usage & Resolution